Immunic Therapeutics logo

Vice President, Patient Advocacy & Corporate Communications

Immunic Therapeutics

Any City, USRemotePosted 31 days ago$310,000 - $350,000/year
Full TimeDirector & AboveCorporate FunctionsBiotechnology
Original posting ↗

Summary

We are seeking an accomplished Vice President, Patient Advocacy & Corporate Communications to lead an integrated strategy spanning Patient Advocacy, External Engagement, Government Affairs, and Corporate Communications. This executive will ensure the patient perspective meaningfully shapes Immunic's strategy, culture, and external communications, deepen relationships with the multiple sclerosis community, and strengthen the company's reputation as it advances toward late-stage clinical, regulatory, and commercial milestones. The VP will serve as a senior enterprise leader and trusted advisor to the executive team, building and leading a high-performing team including a senior communications leader.

Job description

Summary

We are seeking an accomplished Vice President, Patient Advocacy & Corporate Communications to lead an integrated strategy spanning Patient Advocacy, External Engagement, Government Affairs, and Corporate Communications. This executive will ensure the patient perspective meaningfully shapes Immunic's strategy, culture, and external communications, deepen relationships with the multiple sclerosis community, and strengthen the company's reputation as it advances toward late-stage clinical, regulatory, and commercial milestones. The VP will serve as a senior enterprise leader and trusted advisor to the executive team, building and leading a high-performing team including a senior communications leader.

Responsibilities

  • Develop and lead Immunic's global patient advocacy strategy, starting with the multiple sclerosis community, and build trusted relationships with patient organizations, leaders, and caregivers.
  • Establish systematic approaches (advisory boards, listening initiatives, research) for incorporating the patient voice into clinical, medical, access, and commercial strategy.
  • Provide strategic leadership over corporate communications, including reputation, media relations, executive and internal communications, digital/social, and issues management.
  • Develop and evolve Immunic's corporate narrative and messaging, and oversee integrated communications around clinical data, regulatory milestones, and corporate developments.
  • Serve as senior communications advisor to the CEO, President & COO, and executive team, supporting executive positioning and high-profile external engagement.
  • Build an integrated approach connecting corporate storytelling with authentic patient experiences across all communications channels and materials.
  • Represent Immunic externally with patient organizations, industry associations, and policymakers, and monitor policy issues affecting MS patients and the company.
  • Serve as a member of the senior leadership team, bringing external and patient perspectives into enterprise strategy and major milestone planning.
  • Build, lead, and develop a high-performing Patient Advocacy & Corporate Communications organization, including talent, budgets, agencies, and performance metrics.

Qualifications & Education

  • Bachelor's degree required; advanced degree in communications, public affairs, business, healthcare, or life sciences preferred.
  • 15+ years of progressive leadership experience in biotechnology, pharmaceuticals, healthcare, patient advocacy, or corporate communications.
  • Deep, demonstrated expertise spanning both patient advocacy and corporate communications, with the breadth to lead an integrated function.
  • Strong understanding of drug development, regulatory, and commercialization milestones, and the ability to translate complex science into compelling narratives.
  • Proven experience advising CEOs and senior executives on sensitive, high-profile communications and stakeholder matters.
  • Demonstrated success building functions, teams, and operating models within a growing organization, including managing agencies and budgets.
  • Experience in multiple sclerosis, neuroscience, immunology, or specialty therapeutics strongly preferred, with existing MS advocacy community relationships highly desirable.

Requirements

  • Bachelor's degree required; advanced degree in communications, public affairs, business, healthcare, or life sciences preferred.
  • 15+ years of progressive leadership experience in biotechnology, pharmaceuticals, healthcare, patient advocacy, or corporate communications.
  • Deep, demonstrated expertise spanning both patient advocacy and corporate communications, with the breadth to lead an integrated function.
  • Strong understanding of drug development, regulatory, and commercialization milestones, and the ability to translate complex science into compelling narratives.
  • Proven experience advising CEOs and senior executives on sensitive, high-profile communications and stakeholder matters.
  • Demonstrated success building functions, teams, and operating models within a growing organization, including managing agencies and budgets.
  • Experience in multiple sclerosis, neuroscience, immunology, or specialty therapeutics strongly preferred, with existing MS advocacy community relationships highly desirable.

Benefits

  • Equity
  • Bonus

Company overview

Immunic Therapeutics (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for chronic inflammatory and autoimmune diseases, with a primary focus on neurologic conditions such as multiple sclerosis (MS). Headquartered in New York City with additional operations in Gräfelfing, Germany, the company is dedicated to advancing a clinical pipeline of orally administered, small molecule therapeutics. Its lead program, vidofludimus calcium (IMU-838), is a first-in-class oral therapy that combines neuroprotective effects through nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral properties via selective dihydroorotate dehydrogenase (DHODH) inhibition. Vidofludimus calcium is currently in Phase 3 clinical trials (ENSURE program) for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and has demonstrated promising therapeutic activity in Phase 2 trials for both relapsing-remitting and progressive MS. The company's pipeline also includes earlier-stage programs, such as IMU-856 targeting gastrointestinal diseases and IMU-381 for gastrointestinal applications. Founded in 2016, Immunic employs approximately 51-200 people and is transitioning toward becoming a fully integrated commercial-stage biotechnology company.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.